Established in 2006, Hainan Zhongyu Pharmaceutical Co., Ltd. was formerly known as Hainan Wanhe Pharmaceutical Co., Ltd. and was renamed as Hainan Zhongyu Pharmaceutical Co., Ltd. in May 2010. The company mainly engages in the production and operation of chemical medicine preparation, pharmaceutical raw materials and Chinese medicine preparations and new drug R & D, which is an emerging private enterprise.    
    The company mainly produces tablets, granules, capsules and other solid preparations, lyophilized powder for injection, small volume injections and raw materials, etc.
    The company has a registered capital of 50 million yuan and has a a number of functional departments including quality management department, production management department, R & D synthesis department, equipment management department, finance department and logistics management department.
    The company's main products include: diclofenac sodium lidocaine hydrochloride for injection (Yuwutai), Xiaoaiping chewable tablets, Xiaoaiping tablets, Lemai capsules, Kangguzhengsheng tablets, Xiaoyanlidan tablets, Xiasangju granules, Gaomaoqing capsules and so on. Now it has developed and declared a few pharmaceutical raw materials and preparations with good market prospects, which have entered the approval procedure of the State Food and Drug Administration, laying the foundation for long-term development.
Since the establishment, in the principle of "people-oriented and social services", the company has rooted in Taling Industrial Development Zone, Ding'an, Hainan. It covers an area of about 50mu, about 33215m2, including a building area of 10000m2, green area of 21797m2 and greening rate of more than 66%.
    The company passed the new national GMP certification of freeze-dried powder production line in December 2012 (certificate No. CN20120127), and passed the new GMP of tablets, capsules and granules. After putting into the production, the output value of the first and second year is expected to be around 60 million yuan and the output can reach 200 million yuan or more annually.
    As a young pharmaceutical company, the company is mature market-oriented and regards the development of new drugs as the foundation for enterprise development. Currently, it is declaring a first sort drug and 2 third sort drugs and more than 10 characteristics of 6 class generic drugs with good market prospect. We have the confidence to build the company into a modern, efficient and standard pharmaceutical company with strong market competitiveness.